{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canagliflozin&page=4", "query": { "intervention": "Canagliflozin", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 83, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canagliflozin&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Canagliflozin&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T00:11:20.159Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03627039", "title": "Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "SGLT2", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20000, "start_date": "2018-09-01", "completion_date": "2020-08-01", "has_results": false, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03627039" }, { "nct_id": "NCT01137812", "title": "The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Sitagliptin 100 mg", "type": "DRUG" }, { "name": "Canagliflozin 300 mg", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Sulphonylurea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 756, "start_date": "2010-07", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2015-01-15", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 85, "location_summary": "Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01137812" }, { "nct_id": "NCT01106651", "title": "A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin 100 mg", "type": "DRUG" }, { "name": "Canagliflozin 300 mg", "type": "DRUG" }, { "name": "Antihyperglycemic agent(s)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "55 Years to 80 Years" }, "enrollment_count": 716, "start_date": "2010-06", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 34, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" }, { "city": "Citrus Heights", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106651" }, { "nct_id": "NCT05161429", "title": "BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "DPP4", "type": "DRUG" }, { "name": "GLP-1 receptor agonist", "type": "DRUG" }, { "name": "Basal Insulin", "type": "DRUG" }, { "name": "SLGT2", "type": "DRUG" }, { "name": "SU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 550000, "start_date": "2021-07-01", "completion_date": "2024-06-30", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 5, "location_summary": "Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more", "locations": [ { "city": "Wilmington", "state": "Delaware" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Beachwood", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05161429" }, { "nct_id": "NCT02065752", "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Canagliflozin, 100 mg", "type": "DRUG" }, { "name": "Metformin XR, 500 mg", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 1, 50 mg/500 mg", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 2, 50 mg/500 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 2, "start_date": "2014-02", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-06-17", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065752" }, { "nct_id": "NCT01381887", "title": "A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin 300mg/Placebo", "type": "DRUG" }, { "name": "Canagliflozin 300mg/Canagliflozin 150mg", "type": "DRUG" }, { "name": "Canagliflozin 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "25 Years to 70 Years" }, "enrollment_count": 37, "start_date": "2011-06", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2013-04-22", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 5, "location_summary": "Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miramar", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01381887" }, { "nct_id": "NCT02039245", "title": "Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "CANA/MET XR FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2014-01", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 1, "location_summary": "Neptune City, New Jersey", "locations": [ { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02039245" }, { "nct_id": "NCT02071368", "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin, 300 mg", "type": "DRUG" }, { "name": "Metformin XR, 500 mg", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 1, 150 mg/500", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 2, 150 mg/500 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 3, "start_date": "2014-02", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-07-01", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071368" }, { "nct_id": "NCT02139943", "title": "A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Canagliflozin 100 mg", "type": "DRUG" }, { "name": "Canagliflozin 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 352, "start_date": "2014-05", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-07-18", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 46, "location_summary": "Little Rock, Arkansas • Concord, California • La Jolla, California + 43 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02139943" }, { "nct_id": "NCT03936010", "title": "Replication of the CANVAS Diabetes Trial in Healthcare Claims", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "DPP-4 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152202, "start_date": "2017-09-22", "completion_date": "2021-02-18", "has_results": false, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-10-06T00:11:20.159Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03936010" } ] }